The Epilepsy Foundation’s Clinical Trials Portal connects participants to current trials and observational studies to help accelerate development and testing of new treatments.
In this video, the Epilepsy Foundation’s Chief Scientific Officer Dr. Jacqueline French introduces one of her patients, Sally. You'll hear Sally and her family share their experience participating in a clinical trial similar to the ones listed below. Watch the video, then scroll down to find some trials that are recruiting or to search for another trial that’s right for you.
Select any filter and click on Apply to see results
The following are studies that are currently searching for participants.
Please contact the research study staff directly for the most current information.
The FAiRE program of clinical trials is exploring whether an investigational drug (ZX008) can improve seizure control in children and young adults with Dravet syndrome. FAiRE stands for “Fenfluramine Assessment in Rare Epilepsy.” The goal of the ZX008-1501/1504 trials is to show that ZX008 is a safe and effective treatment for children and adolescents with Dravet syndrome when added on to their other seizure medications.
The Rare Epilepsy Network (REN) is a partnership between rare epilepsy organizations, the Epilepsy Foundation, Columbia University, and Research Triangle International to conduct research to improve outcomes of rare conditions associated with epilepsy and seizures.
This project will look at individuals in the early stages of treatment for focal epilepsy to study treatment responses and the likelihood of developing drug resistant epilepsy. Using this information, HEP hopes to discover biomarkers that will predict how people with focal seizures respond to treatment.
This Phase IIb trial will test whether earlier treatment versus standard treatment with vigabatrin in infants with tuberous sclerosis complex (TSC) will have a positive impact on developmental outcomes at 24 months of age. It also tests whether early treatment prevents or lowers the risk of developing infantile spasms and refractory seizures. It is a randomized, double-blind, placebo-controlled clinical trial design. Infants under the age of 6 months diagnosed with TSC but without history of seizures or infantile spasms may be eligible.
The University of Virginia Comprehensive Epilepsy Program is conducting a research study on the use of focused ultrasound to treat deep lesions in the brain causing intractable epilepsy in adults 18 to 80 years old. The study will evaluate the effectiveness and safety of an investigational device that uses ultrasound or sound waves from outside the head to treat seizures that are not well controlled by medication and are due to a small growth of abnormal cells in the middle of the brain, most commonly hypothalamic hamartomas.
Epilepsy is one of the most common neurological disorders affecting women of childbearing age. Poor pregnancy outcomes are increased in these women and their children. The MONEAD study will increase our knowledge on multiple levels to improve care and reduce negative outcomes in these mothers and children. An overall goal of this study is to establish the relationship between antiepileptic drug exposure and outcomes in the mother and child. An additional goal is to describe and explain the variability in antiepileptic drug exposure and response.
Epilepsy surgery is an alternative for some people whose seizures cannot be controlled by anticonvulsant medications. Radiosurgery is a minimally-invasive radiation procedure used to treat tumors and other abnormalities of the brain, and is currently being investigated as an alternative to open surgery treatment for a very select group of patients with medically refractory partial epilepsy. The Gamma Knife® radiosurgery instrument used in this study uses tightly focused beams of radiation to injure the surgical target, rather than removing it with open surgery. Gamma Knife radiosurgery does not require an inpatient hospital stay. This trial, sponsored by the National Institutes of Health and Elekta, the company that manufactures the Gamma Knife, was designed to compare advantages and disadvantages of open surgery versus radiosurgery. The ROSE Trial (Radiosurgery or Open Surgery for Epilepsy) is in follow-up phase at major epilepsy centers across the US and Canada.
EPGP is a large-scale, international, multi-institutional, collaborative research project aimed at advancing the understanding of the genetic basis of the most common forms of epilepsy. The overall goal of EPGP was to collect detailed, high quality phenotypic (i.e., characteristics of individuals, from the molecular level to the whole person) information on persons with epilepsy and to compare the phenotypic information with genomic information. EPGP provides a resource that may lead to many discoveries related to the diagnosis and treatment of epilepsy, including the eventual development of new therapies based on a better understanding of causes of the disorder.
This Clinical Trial Portal includes all studies for which study sponsors have requested inclusion and which meet the Epilepsy Foundation's inclusion criteria. In addition, some sponsors whose studies have been accepted for inclusion in the portal have made a payment to the Epilepsy Foundation in order to receive the Foundation's additional assistance in promoting the study, in order to facilitate patient enrollment. The decision to participate in a particular study should only be made after thorough review of all available study materials, including the relevant study protocol, and discussion with the patient's physician.